State of the art management of metastatic gastroesophageal cancer

Adrian Murphy, David Lynch, Ronan Joseph Kelly

Research output: Contribution to journalReview article

Abstract

The anatomical locations of upper gastrointestinal (GI) tumors have changed remarkably in the western world and reflect the increasing impact of obesity and gastroesophageal (GE) reflux rather than infectious etiologies. Incidence rates of GE tumors are rising rapidly and survival rates for patients with metastatic disease remain poor. Traditionally, cytotoxic chemotherapy has had some survival advantages but increasingly complex combination regimens are limited by toxicities. The advent of molecularly targeted therapy has provided additional options for patients with advanced disease including trastuzumab and ramucirumab. There has also been detailed molecular characterization of upper GI tumors which hopefully will result in improved tailoring of clinical trial design accounting for the heterogeneity inherent in GE tumors. While numerous targeted therapies are currently being studied in clinical trials, there is much excitement regarding the role of immunotherapy in GE cancers. Although further investigation is warranted, it represents a promising avenue for patients with advanced GE tumors.

Original languageEnglish (US)
Article number236
JournalAnnals of Translational Medicine
Volume3
Issue number16
DOIs
StatePublished - Sep 1 2015

Keywords

  • Chemotherapy
  • Esophageal cancer
  • Gastric cancer
  • Immunotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'State of the art management of metastatic gastroesophageal cancer'. Together they form a unique fingerprint.

  • Cite this